Skip to content
Screener

Relay Therapeutics, Inc. RLAY Q2 2025 earnings

Reported August 7, 2025 · After market close

Revenue$677.0KBeat by $662.7K
EPS-$0.41Beat by $0.08
Revenue estimate$14.3K
EPS estimate-$0.49

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$1.6M
EPS estimate-$0.40

Financials

Q2 2025

Income statement

See full
Revenue$677.0K—
Operating income-$76.8M+23.7%
Net income-$70.4M+23.7%
EPS (diluted)-$0.41+40.6%

Balance sheet

See full
Cash & equivalents$113.9M-15.0%
Total debt$34.2M-33.1%
Total equity$665.7M-2.4%
Total assets$728.8M-5.7%

Cash flow

See full
Operating cash flow-$55.3M+16.1%
CapEx$26.0K+136%
Free cash flow-$55.3M+16.0%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$567.48M-33.5%
Enterprise value$487.72M-36.7%
P/S67.9×+43.7×

Profitability

See full
Operating margin-4,105.6%-6,108pp
Net margin-3,728.4%-5,533pp
FCF margin-3,136.2%-4,788pp

Returns & leverage

See full
Return on equity-46.2%+3.4pp
Debt / equity0.1×0.0×
Current ratio20.9×+5.3×

FAQ

When did Relay Therapeutics, Inc. report Q2 2025 earnings?
Relay Therapeutics, Inc. (RLAY) reported Q2 2025 earnings on August 7, 2025 after market close.
What were Relay Therapeutics, Inc.'s Q2 2025 revenue and EPS?
Relay Therapeutics, Inc. reported revenue of $677.0K and eps of $-0.41 for Q2 2025.
Did Relay Therapeutics, Inc. beat estimates in Q2 2025?
Revenue beat the consensus estimate of $14.3K by $662.7K. EPS beat the consensus estimate of $-0.49 by $0.08.
How did Relay Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 40.6% from $-0.69.
Where can I find Relay Therapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-105022) and the 10-Q periodic report (0000950170-25-105054) directly on SEC EDGAR. The filing index links above go to sec.gov.